Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
Navarro-Yepes J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, Singareeka Raghavendra A, Wang Y, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S, Tripathy D, Keyomarsi K. Navarro-Yepes J, et al. Among authors: damodaran s. Cancer Res. 2023 Oct 2;83(19):3264-3283. doi: 10.1158/0008-5472.CAN-23-0705. Cancer Res. 2023. PMID: 37384539 Free PMC article.
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer.
Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K. Meric-Bernstam F, et al. Among authors: damodaran s. JCO Precis Oncol. 2018;2018:PO.17.00245. doi: 10.1200/PO.17.00245. Epub 2018 Apr 25. JCO Precis Oncol. 2018. PMID: 30035249 Free PMC article.
Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer.
Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Ueno NT, et al. Among authors: damodaran s. Cancer Med. 2020 Feb;9(3):1025-1032. doi: 10.1002/cam4.2780. Epub 2019 Dec 18. Cancer Med. 2020. PMID: 31849202 Free PMC article. Clinical Trial.
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.
Akcakanat A, Zheng X, Cruz Pico CX, Kim TB, Chen K, Korkut A, Sahin A, Holla V, Tarco E, Singh G, Damodaran S, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Akcakanat A, et al. Among authors: damodaran s. Clin Cancer Res. 2021 Jun 1;27(11):3243-3252. doi: 10.1158/1078-0432.CCR-20-4048. Epub 2021 Mar 29. Clin Cancer Res. 2021. PMID: 33782032 Free PMC article.
Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, Hunt KK, Shen Y, Tripathy D, Keyomarsi K. Ha MJ, et al. Among authors: damodaran s. Int J Cancer. 2022 Jun 15;150(12):2025-2037. doi: 10.1002/ijc.33959. Epub 2022 Mar 3. Int J Cancer. 2022. PMID: 35133007 Free PMC article.
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer.
Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R Jr, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Abuhadra N, et al. Among authors: damodaran s. Cancers (Basel). 2022 Mar 4;14(5):1323. doi: 10.3390/cancers14051323. Cancers (Basel). 2022. PMID: 35267631 Free PMC article.
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Nelson BE, et al. Among authors: damodaran s. Cancer. 2023 Jul 15;129(14):2201-2213. doi: 10.1002/cncr.34773. Epub 2023 Apr 4. Cancer. 2023. PMID: 37016732 Clinical Trial.
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.
Abuhadra N, Sun R, Bassett RL Jr, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Abuhadra N, et al. Among authors: damodaran s. Invest New Drugs. 2023 Jun;41(3):391-401. doi: 10.1007/s10637-023-01357-4. Epub 2023 Apr 12. Invest New Drugs. 2023. PMID: 37043123 Clinical Trial. No abstract available.
206 results